share_log

HC Wainwright & Co. Maintains Buy on Cullinan Oncology, Lowers Price Target to $49

HC Wainwright & Co. Maintains Buy on Cullinan Oncology, Lowers Price Target to $49

HC Wainwright & Co.維持對庫裏南腫瘤學的買入,將目標價下調至49美元
Benzinga ·  2023/05/12 06:22

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price target from $50 to $49.

HC Wainwright & Co. 分析師愛德華·懷特維持庫裏南腫瘤學(納斯達克股票代碼:CGEM)的買入,並將目標股價從50美元下調至49美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論